Synovial and mucosal immunopathology in spondyloarthritis

Advances in Experimental Medicine and Biology

Volumn 649, Issue , 2009, Pages 71-84

  Vandooren, Bernard ^a   Tak, Paul P ^a   Baeten, Dominique ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD163 ANTIGEN; CD68 ANTIGEN; DICKKOPF 1 PROTEIN; HLA B27 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN MIA; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; REGULATOR PROTEIN; SALAZOSULFAPYRIDINE; STROMELYSIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ARTICLE; BONE REMODELING; CARD15 GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENTERITIS; ENTHESITIS; GENE; GENETIC PREDISPOSITION; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; INTERLEUKIN 23 RECEPTOR GENE; MECHANICAL STRESS; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RECEPTOR GENE; SPONDYLOARTHROPATHY; SYNOVIUM; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; BONE; HISTOLOGY; IMMUNOLOGY; INTESTINE MUCOSA; JOINT; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SPONDYLARTHRITIS;

BIOLOGICAL MARKERS; BONE AND BONES; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA; JOINTS; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE;

EID: 70349570596     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0298-6_5     Document Type: Article

References (122)

1. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006; 20(3):451-71. (Pubitemid 43843072)
2. Cawley MI, Chalmers TM, Kellgren JH et al. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis 1972; 31:345-58.
3. Francois RJ. Microradiographic study of the intervertebral bridges in ankylosing spondylitis and in the normal sacrum. Ann Rheum Dis 1965; 24:481-9.
4. de Vlam K, Mielants H, Verstaete KL et al. The zygapophyseal joint determines morphology of the enthesophyte. J Rheumatol 2000; 27:1732-9. (Pubitemid 30462820)
5. Appel H, Kuhne M, Spiekermann S et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845-51. (Pubitemid 44497763)
6. Francois RJ, Gardner DL, Degrave EJ et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000; 43:2011-24.
7. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499-505.
8. Appel H, Kuhne M, Spiekermann S et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006; 54:1805-13. (Pubitemid 43877930)
9. Baeten D, Demetter P, Cuvelier C et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59:945-53.
10. Kruithof E, Baeten D, De Rycke L et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7:R569-80.
11. Smeets TJ, Dolhain RJ, Breedveld FC et al. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998; 186:75-81. (Pubitemid 28407491)
12. van Kuijk AW, Reinders-Blankert P, Smeets TJ et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65:1551-7. (Pubitemid 44799664)
13. Cunnane G, Bresnihan B, FitzGerald O. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis Rheum 1998; 41:180-2. (Pubitemid 28041939)
14. Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409:198-201. (Pubitemid 32144285)
15. Baeten D, Kruithof E, De Rycke L et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005; 7:R359-69.
16. Kruithof E, De Rycke L, Vandooren B et al. OMERACT Special Interest Group on Synovial Analysis in Clinical Trials. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006; 54:1795-804. (Pubitemid 43877929)
17. Reece RJ, Canete JD, Parsons WJ et al. Distinct vascular patterns of early synovitis in psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999; 42:1481-4. (Pubitemid 30265607)
18. Canete JD, Rodriguez JR, Salvador G et al. Diagnostic usefulness of synovial vascular morphology in chronic arthritis. A systematic survey of 100 cases. Semin Arthritis Rheum 2003; 32:378-87. (Pubitemid 36759365)
19. Francois RJ, Braun J, Khan MA. Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. Curr Opin Rheumatol 2001; 13:255-64. (Pubitemid 32831815)
20. McGonagle D, Marzo-Ortega H, O'Connor P et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002; 61:534-7. (Pubitemid 34539099)
21. Laloux L, Voisin MC, Allain J et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60:316-21. (Pubitemid 32242741)
22. Said-Nahal R, Miceli-Richard C, D'Agostino MA et al. Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis Rheum 2001; 45:478-84. (Pubitemid 33140582)
23. Calin A, Marder A, Marks S et al. Familial aggregation of Reiter's syndrome and ankylosing spondylitis: a comparative study. J Rheumatol 1984; 11:672-7. (Pubitemid 15215057)
24. Gossec L, van der Heijde D, Melian A et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64:1563-7. (Pubitemid 41532038)
25. Braun J, Zochling J, Baraliakos X et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65:1147-53. (Pubitemid 44277387)
26. Clegg DO, Reda DJ, Weisman MH et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2004-12.
27. Vandooren B, Kruithof E, Yu DT et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50:2942-53. (Pubitemid 39209533)
28. Maksymowych WP, Landewe R, Conner-Spady B et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56:1846-53. (Pubitemid 47110384)
29. Brophy S, Mackay K, Al-Saidi A et al. The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 2002; 29:1236-43. (Pubitemid 34601961)
30. Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-27.
31. van der Linden S. Spondyloarthropathies. In: Kelley, Harris, Ruddy and Sledge. Textbook of Rheumatology. 5th Ed. 1997; 969-82.
32. Polzer K, Schett G, Zwerina J. The lonely death: chondrocyte apoptosis in TNF-induced arthritis. Autoimmunity 2007; 40:333-6. (Pubitemid 46845533)
33. Zwerina J, Redlich K, Polzer K et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104:11742-7.
34. Redlich K, Hayer S, Ricci R et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110:1419-27. (Pubitemid 35396913)
35. Diarra D, Stolina M, Polzer K et al. Dickkopf-1 is a master regulator of joint remodeling Nat Med 2007; 13:156-63.
36. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-99. (Pubitemid 33062512)
37. Lam J, Takeshita S, Barker JE et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-8. (Pubitemid 32038586)
38. Wei S, Kitaura H, Zhou P et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-90. (Pubitemid 40385470)
39. Rountree RB, Schoor M, Chen H et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol 2004; 2:e355.
40. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005; 115:1571-9. (Pubitemid 40814665)
41. van Beuningen HM, Glansbeek HL, van der Kraan PM et al. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage 1998; 6:306-17. (Pubitemid 28404971)
42. van Beuningen HM, van der Kraan PM, Arntz OJ et al. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 1994; 71:279-90.
43. Valencia X, Higgins JM, Kiener HP et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004; 200:1673-9. (Pubitemid 40094191)
44. Lee DM, Kiener HP, Agarwal SK et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315:1006-10. (Pubitemid 46281192)
45. Vandooren B, Cantaert T, van Lierop MJ et al. Melanoma Inhibitory Activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammarory cytokines in rheumatoid arthritis. Submitted for publication.
46. Vandooren B, Cantaert T, Noordenbos T et al. The abundant synovial expression of the RANK-RANKL-OPG system in peripheral spondyloarthritis is partially disconnected from inflammation. Arthritis Rheum. In press.
47. Ritchlin CT, Haas-Smith SA, Li P et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-31. (Pubitemid 37074957)
48. Lories RJ, Derese I, Ceuppens JL et al. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammarory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 2003; 48:2807-18. (Pubitemid 37280609)
49. Glansbeek HL, van Beuningen HM, Vitters EL et al. Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1 alpha effects on proteoglycan synthesis and content. Arthritis Rheum 1997; 40:1020-8. (Pubitemid 27242288)
50. Chen Y, Whetstone HC, Youn A et al. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem 2007; 282:526-33. (Pubitemid 47076655)
51. Ribbens C, Martiny Porras M, Franchimont N et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002; 61:161-6. (Pubitemid 34098433)
52. Chen CH, Lin KC, Yu DT et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitiS: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 2006; 45:414-20.
53. Yang C, Gu J, Rihl M et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004; 51:691-9. (Pubitemid 39372026)
54. Kim TH, Stone M, Payne U et al. Inman Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005; 52:885-91. (Pubitemid 40365112)
55. Maksymowych WP, Poole AR, Hiebert L et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005; 32:1911-7. (Pubitemid 41429021)
56. Olsen AK, Sondergaard BC, Byrjalsen I et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007; 15:335-42. (Pubitemid 46238248)
57. Grisar J, Bernecker PM, Aringer M et al. Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29:1430-6. (Pubitemid 34755610)
58. Woo JH, Lee HJ, Sung IH et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007; 34:1753-9.
59. Baeten D, Kruithof E, De Rycke L et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis bysynovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004; 50:2931-41. (Pubitemid 39209532)
60. Baeten D, Kruithof E, De Rycke L et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005; 7:R359-69.
61. Kruithof E, De Rycke L, Vandooren B et al. OMERACT Special Interest Group on Synovial Analysis in Clinical Trials. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006; 54:1795-804. (Pubitemid 43877929)
62. Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol 2006; 20:593-9. (Pubitemid 43843065)
63. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology 2004; 126:1504-17. (Pubitemid 38649869)
64. Porcher R, Said-Nahal R, D'Agostino MA et al. Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. Arthritis Rheum 2005; 53:263-71. (Pubitemid 40530168)
65. de Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27:2860-5.
66. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603. (Pubitemid 32531408)
67. Laukens D, Peeters H, Marichal D et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2005; 64:930-5. (Pubitemid 40733921)
68. Bjarnason I, Helgason KO, Geirsson AJ et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003; 125:1598-605. (Pubitemid 37500423)
69. Peeters H, Vander Cruyssen B, Mielants H et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroemerol Hepatol 2007; [Epub ahead of print].
70. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-3. (Pubitemid 44871953)
71. Capon F, Di Meglio P, Szaub J et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122:201-206. (Pubitemid 47241785)
72. Brown MA. Nature Genetics. In Press.
73. Mannon PJ, Fuss IJ, Mayer L et al. Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069-79. (Pubitemid 39482500)
74. Krueger GG, Langley RG, Leonardi C et al. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580-92. (Pubitemid 46220818)
75. De Vos M, Cuvelier C, Mielants H et al. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989; 96:339-44. (Pubitemid 19045264)
76. Demetter P, Van Huysse JA, De Keyser F et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol 2002; 198:517-22. (Pubitemid 35452516)
77. Becker C, Wirtz S, Blessing M et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003; 112:693-706. (Pubitemid 38057710)
78. Demetter P, De Vos M, Van Huysse JA et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005; 64:321-4. (Pubitemid 40193638)
79. Baeten D, Demetter P, Cuvelier CA et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002; 196:343-50. (Pubitemid 34189425)
80. Van Damme N, Elewaut D, Baeten D et al. Gut mucosal T-cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol 2001; 19:681-7. (Pubitemid 34026832)
81. Van Damme N, De Keyser F, Demetter P et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol 2001; 125:383-90. (Pubitemid 34155434)
82. Canete JD, Martinez SE, Farres J et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000; 59:263-8. (Pubitemid 30305567)
83. Baeten D, Van Damme N, Van den Bosch F et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001; 60:750-5. (Pubitemid 32685875)
84. Rudwaleit M, Siegert S, Yin Z et al. Low T-cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60(1):36-42. (Pubitemid 32038951)
85. Baeten D, De Keyser F, Mielants H et al. Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 2002; 14:342-7. (Pubitemid 34693975)
86. May E, Marker-Hermann E, Wittig BM et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000; 119:1745-55. (Pubitemid 32198700)
87. Hammer RE, Maika SD, Richardson JA et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 30:1099-112. (Pubitemid 120034950)
88. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-64. (Pubitemid 24351619)
89. Breban M, Fernandez-Sueiro JL, Richardson JA et al. T-cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156:794-803. (Pubitemid 26028940)
90. Hacquard-Bouder C, Chimenti MS, Giquel B et al. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T-cells: selective impairment of costimulatory molecule engagement by mature HLA-B27. Arthritis Rheum 2007; 56:1478-89. (Pubitemid 46764076)
91. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216. (Pubitemid 34293424)
92. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725-34.
93. De Rycke L, Kruithof E, Vandooren B et al. Pathogenesis of spondyloarthritis: insights from synovial membrane studies. Curr Rheumatol Rep 2006; 8:275-82. (Pubitemid 44623954)
94. Liew FY, Xu D, Brint EK et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-58. (Pubitemid 40835033)
95. Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78-83. (Pubitemid 32843491)
96. Mansell A, Smith R, Doyle SL et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006; 7:148-55. (Pubitemid 43135880)
97. Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350-4.
98. Boone DL, Turer EE, Lee EG et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5:1052-60. (Pubitemid 41057725)
99. Trompouki E, Hatzivassiliou E, Tsichritzis T et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424:793-6. (Pubitemid 37021710)
100. Yoshida H, Jono H, Kai H et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280:41111-21. (Pubitemid 41780606)
101. Inman RD, Rohekar S, Reena R et al. TLR2, but not TLR4, variants are associated with reactive arthritis. Poster presentation American College of Rheumatology meeting 2007.
102. De Rycke L, Vandooren B, Kruithof E et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005; 52:2146-58. (Pubitemid 40994338)
103. Watanabe T, Kitani A, Murray PJ et al. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006; 25:473-85. (Pubitemid 44355006)
104. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95. (Pubitemid 41057715)
105. Kim KD, Zhao J, Auh S et al. Adaptive immune cells temper initial innate responses. Nat Med 2007; 13:1248-52 (Pubitemid 47530627)
106. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253-6. (Pubitemid 32694733)
107. Rimoldi M, Chieppa M, Salucci V et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005; 6:507-14. (Pubitemid 41716764)
108. Hart AL, Al-Hassi HO, Rigby RJ et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129:50-65. (Pubitemid 41002042)
109. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th 17 cells. J Exp Med 2007; 204:1849-61. (Pubitemid 47240944)
110. Elson CO, Cong Y, Weaver CT et al. Monoclonal anti-interleukin 23 reverses active colitis in a T-cell-mediated model in mice. Gastroenterology 2007; 132:2359-70. (Pubitemid 46890867)
111. Timms AE, Crane AM, Sims AM et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75:587-95. (Pubitemid 39244773)
112. Maksymowych WP, Rahman P, Reeve JP et al. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 2006; 54:974-85.
113. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat Immunol 2007; 8:950-7. (Pubitemid 47300009)
114. Benjamin M, Toumi H, Suzuki D et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007; 56:224-33. (Pubitemid 46106196)
115. Corps AN, Robinson AH, Movin T et al. Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy. Rheumatology 2006; 45:291-4. (Pubitemid 43372843)
116. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-33. (Pubitemid 41134165)
117. Dossumbekova A, Anghelina M, Madhavan S et al. Biomechanical signals inhibit IKK activity to attenuate NF-kappaB transcription activity in inflamed chondrocytes. Arthritis Rheum 2007; 56:3284-3296. (Pubitemid 47592095)
118. Agarwal S, Deschner J, Long P et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 2004; 50:3541-8. (Pubitemid 39488679)
119. Yang XO, Panopoulos AD, Nurieva R et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T-cells. J Biol Chem 2007; 282:9358-63. (Pubitemid 47104613)
120. Laitio P, Virtala M, Salmi M et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 1997; 27:1331-8. (Pubitemid 27254821)
121. Turner MJ, Sowders DP, DeLay ML et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005; 175:2438-48. (Pubitemid 41113854)
122. Tran TM, Dorris ML, Satumtira N et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis withour colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006; 54:1317-27. (Pubitemid 43672945)